The New England journal of medicine, 2022-02, Vol.386 (5), p.449-462
- Doki, Yuichiro
- Ajani, Jaffer A
- Kato, Ken
- Xu, Jianming
- Wyrwicz, Lucjan
- Motoyama, Satoru
- Ogata, Takashi
- Kawakami, Hisato
- Hsu, Chih-Hung
- Adenis, Antoine
- El Hajbi, Farid
- Di Bartolomeo, Maria
- Braghiroli, Maria I
- Holtved, Eva
- Ostoich, Sandra A
- Kim, Hye R
- Ueno, Masaki
- Mansoor, Wasat
- Yang, Wen-Chi
- Liu, Tianshu
- Bridgewater, John
- Makino, Tomoki
- Xynos, Ioannis
- Liu, Xuan
- Lei, Ming
- Kondo, Kaoru
- Patel, Apurva
- Gricar, Joseph
- Chau, Ian
- Kitagawa, Yuko
2022
Details
- Autor(en) / Beteiligte
- Doki, Yuichiro
- Ajani, Jaffer A
- Kato, Ken
- Xu, Jianming
- Wyrwicz, Lucjan
- Motoyama, Satoru
- Ogata, Takashi
- Kawakami, Hisato
- Hsu, Chih-Hung
- Adenis, Antoine
- El Hajbi, Farid
- Di Bartolomeo, Maria
- Braghiroli, Maria I
- Holtved, Eva
- Ostoich, Sandra A
- Kim, Hye R
- Ueno, Masaki
- Mansoor, Wasat
- Yang, Wen-Chi
- Liu, Tianshu
- Bridgewater, John
- Makino, Tomoki
- Xynos, Ioannis
- Liu, Xuan
- Lei, Ming
- Kondo, Kaoru
- Patel, Apurva
- Gricar, Joseph
- Chau, Ian
- Kitagawa, Yuko
- Titel
- Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
- Ist Teil von
- The New England journal of medicine, 2022-02, Vol.386 (5), p.449-462
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Previously untreated patients with advanced esophageal cancer were randomly assigned to receive chemotherapy alone, chemotherapy plus nivolumab, or nivolumab plus ipilimumab. Among patients with tumor-cell PD-L1 expression of 1% or greater, the two nivolumab regimens resulted in longer overall survival than chemotherapy. The side-effect profile was consistent with past reports on these agents.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2111380Titel-ID: cdi_proquest_miscellaneous_2625272051
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, B7-H1 Antigen - antagonists & inhibitors, Cancer therapies, Carcinoma, Squamous Cell - drug therapy, Carcinoma, Squamous Cell - mortality, Cell death, Chemotherapy, Confidence intervals, Drug therapy, Esophageal Neoplasms - drug therapy, Esophageal Neoplasms - mortality, Esophagus, Female, Gastroenterology, Gastrointestinal Tract Cancer, Hematology, Humans, Immune Checkpoint Inhibitors - administration & dosage, Immune Checkpoint Inhibitors - adverse effects, Ipilimumab - administration & dosage, Ipilimumab - adverse effects, Male, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Nivolumab - administration & dosage, Nivolumab - adverse effects, Oncology, Patients, PD-L1 protein, Progression-Free Survival, Squamous cell carcinoma, Survival Analysis, Treatments in Oncology, Tumors